MariTide: a once-a-month obesity drug in trials
MariTide is an experimental weight-loss injection from Amgen that may work for a whole month per shot. It is still in trials, not approved, and not sold anywhere, including India.
Most weight-loss shots today are taken once a week. What if one shot lasted a whole month? That is the idea behind MariTide. It is a new obesity medicine being studied by a company called Amgen. The full science name is maridebart cafraglutide (say: ma-ri-DE-bart ca-fra-GLU-tide). The short brand name is MariTide. Here is the most important thing first: MariTide is EXPERIMENTAL. It is still in clinical trials. It is NOT approved by any drug regulator. It is NOT sold in India or anywhere else. You cannot buy it. Let us look at what the trials actually found.
What MariTide is, in plain words
MariTide is an injectable medicine for obesity. It works in two ways at once. One part acts like a GLP-1 medicine (the same family as Wegovy and Mounjaro). The other part blocks a related gut signal called GIP. Amgen calls this a 'peptide-antibody conjugate' - a small gut-hormone piece stuck onto an antibody. The antibody makes the drug stay in the body for a long time. Amgen says this 'long half-life' is what could allow one shot per month, or even one shot every 12 weeks, instead of every week. It is given as a small injection under the skin using an autoinjector pen device. In the phase 2 trial, the doses tested were 140 mg, 280 mg, and 420 mg every 4 weeks, plus a 420 mg every-8-weeks arm. The phase 3 programme is now testing dose escalation starting at 21 mg, then 35 mg, then 70 mg over 8 weeks.
MariTide vs current weekly GLP-1 shots
MariTide helps you lose about 20% of your body weight in one year.
it dependsit depends - explained simply. In the phase 2 trial (592 adults, 52 weeks), people with obesity but WITHOUT type 2 diabetes lost between -12.3% and -16.2% of body weight on average, compared with -2.5% on placebo. When the researchers counted only people who stayed on the medicine the whole time, the loss went up to about -19.9% (close to 20%). In people WITH type 2 diabetes, the loss was -8.4% to -12.3% on average. The weight loss had not yet flattened out at 52 weeks, meaning it might keep going. But these are trial averages, not a promise for any one person, and the drug is not approved.
You can get MariTide in India right now if you pay enough.
mostly falsemostly false. MariTide is NOT approved in India. India's drug regulator (CDSCO) has not approved it. It is not sold by any pharmacy, online store, or clinic in India. The only way to receive it is to join a clinical trial, and even those trials are run in selected countries and centres. Anyone offering 'MariTide' for sale in India is almost certainly selling a fake or a different drug. Do not try to buy it online. Do not trust messages or social media sellers claiming they have it.
What an Indian reader should do with this news
The bottom line
MariTide is a promising once-a-month obesity shot still in trials. It showed up to about 20% weight loss in one year in its phase 2 study, but it is NOT approved, NOT available, and NOT in India. Talk to your own doctor about weight-loss options you can actually use today.